Kindeva’s global health security division, Meridian Medical Technologies, LLC, has been awarded a contract valued at up to $226 million by the Defense Logistics Agency (DLA) to supply Antidote Treatment Nerve Agent Autoinjectors (ATNAA), expanding the company’s role in providing medical countermeasures for U.S. military personnel. The agreement provides for the potential delivery of more than three million autoinjectors manufactured at the company’s assembly operations in St. Louis, Missouri.

The DLA manages the procurement and distribution of critical supplies for the U.S. Army, Navy, Air Force, Marine Corps, and other federal agencies. Under the agreement, Kindeva will support the agency’s requirements for the manufacture and delivery of ATNAA devices intended to help protect military personnel against potential chemical threats. ATNAA is designed to deliver two medications, atropine and pralidoxime chloride, for the treatment of poisoning caused by organophosphorus nerve agents and certain organophosphorus insecticides.

Kindeva also manufactures DuoDote, the civilian counterpart to ATNAA. The product is supplied to U.S. government agencies, emergency responders, and more than 30 allied nations preparing for domestic or international mass-casualty incidents. According to the company, ATNAA and DuoDote are the only FDA-approved dual-chamber autoinjectors designed to administer this combination of nerve agent antidotes. The products form part of Kindeva’s broader global health security business, which focuses on manufacturing medical countermeasures for military and civilian preparedness.

Manufacturing under the contract will take place at Kindeva’s St. Louis campus, where the company has established capabilities in pharmaceutical manufacturing and fill-finish operations. The facility is part of a regional network serving pharmaceutical and biotechnology customers. Kindeva’s newer site in Bridgeton, Missouri, specializes in fill-finish production and was named a finalist for the International Society for Pharmaceutical Engineering’s (ISPE) Facility of the Future award in 2025.

David Stevens, CEO of Kindeva, says the contract reinforces the company’s work with the U.S. government to address evolving global security risks. He also pointed to a recent DLA visit to the St. Louis facility, during which the company showcased its manufacturing capabilities and production of medical countermeasures.

Tara Butler, director of government contracts for global health security at Kindeva, attributes the award to more than a year of collaboration and communication with the DLA team. She says the company would continue supporting military requirements for the medical countermeasure.

The contract underscores the role of specialized pharmaceutical manufacturers in maintaining supplies of treatments intended for chemical exposure emergencies. Reliable production and delivery of these products are important to military readiness as well as preparedness for incidents affecting civilian populations. For Kindeva, the agreement adds a significant government supply commitment to its existing work providing antidote autoinjectors to U.S. agencies and international customers.

For more information, visit www.kindevadd.com.